

KRYSTAL™-7

www.KRYSTALprogram.com

Currently Seeking Volunteers

The KRYSTAL-7 Study: A Clinical Study for Patients with Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. is currently seeking patients with locally advanced or metastatic NSCLC whose tumor has tested positive for the *KRAS* G12C mutation for a clinical study of an investigational study drug, MRTX849, which will be given in combination with pembrolizumab, as a potential first-line treatment. Approximately 14% of NSCLC tumors test positive for the *KRAS* G12C mutation. If your tumor has this mutation, you may be eligible to participate.

Not sure if you have the *KRAS* G12C mutation?

Testing is available.

You may be eligible to participate in the clinical study if you meet the following criteria:

- Confirmed diagnosis of NSCLC
- Advanced, unresectable or metastatic NSCLC
- Life expectancy beyond three months
- Tumor must have tested positive for the *KRAS* G12C mutation

If you are eligible to participate, you will receive the following at no cost:

- The investigational study drug (MRTX849)
- Pembrolizumab
- All study-related visits, assessments and procedures
- Reimbursement for study-related travel and expenses may also be provided

To see if the KRYSTAL-7 Study is right for you, please contact:

[Insert Site Contact Information]

[Insert Site Contact Information]

[Insert Site Contact Information]

[Insert Site Contact Information]